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Biological insights from 108
schizophrenia-associated genetic loci
Schizophrenia Working Group of the Psychiatric Genomics Consortium*
Schizophrenia is a highly heritable disorder. Genetic risk is conferred by a large number of alleles, including common
alleles of small effect that might be detected by genome-wide association studies. Here we report a multi-stage schizo-
phrenia genome-wide association study of up to 36,989 cases and 113,075 controls. We identify 128 independent asso-
ciations spanning 108 conservatively defined loci that meet genome-wide significance, 83 of which have not been
previously reported. Associations were enriched among genes expressed in brain, providing biological plausibility for
the findings. Many findings have the potential to provide entirely new insights into aetiology, but associations at DRD2
and several genes involved in glutamatergic neurotransmission highlight molecules of known and potential therapeutic
relevance to schizophrenia, andareconsistentwith leadingpathophysiologicalhypotheses. Independentofgenesexpressed
in brain, associations were enriched among genes expressed in tissues that have important roles in immunity, providing
support for the speculated link between the immune system and schizophrenia.
Schizophrenia has a lifetime risk of around 1%, and is associated with
substantialmorbidityandmortality aswell aspersonal andsocietal costs1–3.
Although pharmacological treatments are available for schizophrenia,
their efficacy is poor formanypatients4.All available antipsychotic drugs
are thought to exert theirmain therapeutic effects through blockade of
the type 2dopaminergic receptor5,6 but, since thediscovery of thismech-
anism over 60 years ago, no new antipsychotic drug of proven efficacy
has been developed based on other targetmolecules. Therapeutic stasis
is in large part a consequence of the fact that the pathophysiology of
schizophrenia is unknown. Identifying the causes of schizophrenia is
therefore a critical step towards improving treatments and outcomes
for those with the disorder.
High heritability points to amajor role for inherited genetic variants
in the aetiology of schizophrenia7,8. Although risk variants range in fre-
quency from common to extremely rare9, estimates10,11 suggest half to a
third of the genetic risk of schizophrenia is indexed by common alleles
genotyped by current genome-wide association study (GWAS) arrays.
Thus, GWAS is potentially an important tool for understanding the
biological underpinnings of schizophrenia.
Todate, around30 schizophrenia-associated loci10–23 havebeen iden-
tified through GWAS. Postulating that sample size is one of the most
important limiting factors inapplyingGWAStoschizophrenia,wecreated
the Schizophrenia Working Group of the Psychiatric Genomics Con-
sortium (PGC). Our primary aim was to combine all available schizo-
phrenia samples with published or unpublishedGWAS genotypes into
a single, systematic analysis24.Herewe report the results of that analysis,
including at least 108 independent genomic loci that exceed genome-
wide significance. Some of the findings support leading pathophysio-
logical hypotheses of schizophrenia or targets of therapeutic relevance,
but most of the findings provide new insights.
108 independent associated loci
Weobtainedgenome-wide genotypedata fromwhichweconstructed 49
ancestrymatched, non-overlappingcase-control samples (46ofEuropean
and three of east Asian ancestry, 34,241 cases and 45,604 controls) and
3 family-based samples of European ancestry (1,235 parent affected-
offspring trios) (SupplementaryTable 1 and SupplementaryMethods).
These comprise the primary PGC GWAS data set. We processed the
genotypes from all studies using unified quality control procedures fol-
lowed by imputation of SNPs and insertion-deletions using the 1000
Genomes Project reference panel25. In each sample, association testing
was conductedusing imputedmarkerdosages andprincipal components
(PCs) to control for population stratification. The results were combined
using an inverse-variance weighted fixed effects model26. After quality
control (imputation INFO score$ 0.6, MAF$ 0.01, and successfully
imputed in$ 20 samples), we considered around 9.5 million variants.
The results are summarized inFig. 1.Toenable acquisitionof large sam-
ples, some groups ascertained cases via clinician diagnosis rather than a
research-based assessment and provided evidence of the validity of this
approach (Supplementary Information)11,13. Post hoc analyses revealed
the pattern of effect sizes for associated loci was similar across different
assessmentmethods andmodesof ascertainment (ExtendedDataFig. 1),
supporting our a priori decision to include samples of this nature.
For the subset of linkage-disequilibrium-independent singlenucleotide
polymorphisms (SNPs)withP, 13 1026 in themeta-analysis,we next
obtained results fromdeCODEgenetics (1,513cases and66,236 controls
of European ancestry).Wedefine linkage-disequilibrium-independent
SNPs as those with low linkage disequilibrium (r2, 0.1) to amore sig-
nificantly associated SNPwithin a 500-kb window. Given high linkage
disequilibrium in the extendedmajorhistocompatibility complex (MHC)
region spans,8Mb,we conservatively includeonly a singleMHCSNP
to represent this locus.ThedeCODEdatawere thencombinedwith those
from the primary GWAS to give a data set of 36,989 cases and 113,075
controls. In this final analysis, 128 linkage-disequilibrium-independent
SNPs exceeded genome-wide significance (P# 53 1028) (Supplemen-
tary Table 2).
As inmeta-analysesof other complex traitswhich identified largenum-
bers of common risk variants27,28, the test statistic distribution fromour
GWASdeviates from the null (ExtendedData Fig. 2). This is consistent
withthepreviouslydocumentedpolygeniccontributiontoschizophrenia10,11.
Thedeviation in the test statistics fromthenull (lGC5 1.47,l10005 1.01)
is only slightly less than expected (lGC5 1.56) under a polygenicmodel
given fully informative genotypes, the current sample size, and the life-
time risk and heritability of schizophrenia29.
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Additional linesof evidence allowus to conclude thedeviationbetween
the observed and null distributions in our primary GWAS indicates a
true polygenic contribution to schizophrenia. First, applying a novel
method30 that uses linkage disequilibrium information to distinguish
between themajor potential sources of test statistic inflation, we found
our results are consistent with polygenic architecture but not popula-
tion stratification (Extended Data Fig. 3). Second, the schizophrenia-
associated alleles at 78% of 234 linkage-disequilibrium-independent
SNPs exceeding P, 13 1026 in the case-control GWAS were again
overrepresented in cases in the independent samples from deCODE.
This degree of consistency between the case-control GWAS and the
replication data is highly unlikely to occur by chance (P5 63 10219).
The tested alleles surpassed theP, 1026 threshold inourGWASbefore
weaddedeither the triosordeCODEdata to themeta-analysis.This trend
test is therefore independent of the primary case-controlGWAS.Third,
analysing the 1,235 parent-proband trios, we again found excess trans-
missionof the schizophrenia-associated allele at 69%of the 263 linkage-
disequilibrium-independent SNPswithP, 13 1026 in the case-control
GWAS. This is again unlikely to occur by chance (P5 13 1029) and
additionally excludes population stratification as fully explaining the
associations reaching our threshold for seeking replication. Fourth, we
used the trios trend data to estimate the expected proportion of true
associations at P, 13 1026 in the discovery GWAS, allowing for the
fact that half of the index SNPs are expected to show the same allelic
trend in the trios by chance, and that some true associations will show
opposite trends given the limited number of trio samples (Supplemen-
taryMethods). Given the observed trend test results, around 67% (95%
confidence interval: 64–73%) or n5 176 of the associations in the scan
at P, 13 1026 are expected to be true, and therefore the number of
associations that will ultimately be validated from this set of SNPs will
be considerably more than those that now meet genome-wide signifi-
cance.Taken together, these analyses indicate that theobserveddeviation
of test statistics from the null primarily represents polygenic association
signal and the considerable excess of associations at the tail of extreme
significance largely correspond to true associations.
Independently associated SNPsdonot translate towell-boundedchro-
mosomal regions.Nevertheless, it is useful todefinephysical boundaries
for the SNPassociations to identify candidate risk genes.Wedefined an
associated locus as the physical region containing all SNPs correlated at
r2. 0.6 with each of the 128 index SNPs. Associated loci within 250 kb
of each other weremerged. This resulted in 108 physically distinct asso-
ciated loci, 83 of which have not been previously implicated in schizo-
phrenia and therefore harbour potential new biological insights into
disease aetiology (Supplementary Table 3; regional plots in Supplemen-
taryFig. 1).Thesignificant regions includeall but5 locipreviously reported
tobegenome-wide significant in large samples (SupplementaryTable 3).
Characterization of associated loci
Of the 108 loci, 75% include protein-coding genes (40%, a single gene)
and a further 8% are within 20 kb of a gene (Supplementary Table 3).
Notable associations relevant tomajor hypotheses of the aetiology and
treatmentof schizophrenia includeDRD2 (the target of all effective anti-
psychotic drugs) andmany genes (for example,GRM3,GRIN2A, SRR,
GRIA1) involved in glutamatergicneurotransmission andsynaptic plas-
ticity. In addition, associations atCACNA1C,CACNB2 andCACNA1I,
which encode voltage-gated calciumchannel subunits, extendprevious
findings implicatingmembers of this family of proteins in schizophrenia
and other psychiatric disorders11,13,31,32. Genes encoding calcium chan-
nels, andproteins involved in glutamatergicneurotransmission and syn-
aptic plasticity have been independently implicated in schizophrenia by
studies of rare genetic variation33–35, suggesting convergence at a broad
functional level between studies of common and rare genetic variation.
Wehighlight in theSupplementaryDiscussiongenesofparticular interest
within associated lociwith respect to current hypotheses of schizophrenia
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Figure 1 | Manhattan plot showing schizophrenia associations. Manhattan
plot of the discovery genome-wide association meta-analysis of 49 case control
samples (34,241 cases and 45,604 controls) and 3 family based association
studies (1,235 parent affected-offspring trios). The x axis is chromosomal
position and the y axis is the significance (–log10 P; 2-tailed) of association
derived by logistic regression. The red line shows the genome-wide significance
level (53 1028). SNPs ingreen are in linkagedisequilibriumwith the index SNPs
(diamonds) which represent independent genome-wide significant associations.
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aetiology or treatment (although we do not imply that these genes are
necessarily the causal elements).
For eachof the schizophrenia-associated loci,we identified a credible
causal set of SNPs (for definition, see SupplementaryMethods)36. In only
10 instances (SupplementaryTable 4)was the association signal credibly
attributable to a known non-synonymous exonic polymorphism. The
apparently limited roleofprotein-coding variants is consistent bothwith
exome sequencing findings33 and with the hypothesis that most asso-
ciated variants detected by GWAS exert their effects through altering
gene expression rather than protein structure37,38 and with the obser-
vation that schizophrenia risk loci are enriched for expression quanti-
tative trait loci (eQTL)39.
To try to identify eQTLs that could explain associations with schizo-
phrenia, we merged the credible causal set of SNPs defined above with
eQTLs fromameta-analysisofhumanbraincortexeQTLstudies (n5550)
andaneQTLstudyofperipheral venousblood (n5 3,754)40 (Supplemen-
taryMethods).Multiple schizophrenia loci contained at least one eQTL
for a genewithin 1Mb of the locus (Supplementary Table 4). However,
in only12 instanceswas the eQTLplausibly causal (two inbrain, andnine
in peripheral blood, one in both). This low proportion suggests that if
most risk variants are regulatory, available eQTL catalogues do not yet
provide power, cellular specificity, or developmental diversity to pro-
vide clear mechanistic hypotheses for follow-up experiments.
The brain and immunity
Tofurther explore the regulatorynatureof the schizophreniaassociations,
wemapped the credible sets (n5 108) of causal variants onto sequences
with epigenetic markers characteristic of active enhancers in 56 differ-
ent tissues and cell lines (SupplementaryMethods). Schizophrenia asso-
ciations were significantly enriched at enhancers active in brain (Fig. 2)
but not in tissues unlikely to be relevant to schizophrenia (for example,
bone, cartilage,kidneyand fibroblasts).Brain tissuesused todefineenhanc-
ers consist of heterogeneous populations of cells. Seeking greater spe-
cificity, we contrasted genes enriched for expression in neurons and
glia using mouse ribotagged lines41. Genes with strong expression in
multiple cortical and striatal neuronal lineages were enriched for asso-
ciations, providing support for an important neuronal pathology in
schizophrenia (Extended Data Fig. 4) but this is not statistically more
significant than, or exclusionary of, contributions fromother lineages42.
Schizophrenia associations were also strongly enriched at enhancers
that are active in tissueswith important immune functions, particularly
B-lymphocyte lineages involved in acquired immunity (CD19andCD20
lines, Fig. 2). These enrichments remain significant even after exclud-
ing the extendedMHC region and regions containing brain enhancers
(enrichment P for CD20, 1026), demonstrating that this finding is
not an artefact of correlation between enhancer elements in different
tissues andnotdrivenby the stronganddiffuseassociationat theextended
MHC. Epidemiological studies have long hinted at a role for immune
dysregulation in schizophrenia, the present findings provide genetic
support for this hypothesis43.
Todevelopadditional biological hypothesesbeyond those that emerge
from inspection of the individual loci, we further undertook a limited
miningof thedata throughgene-set analysis.However, as there isnocon-
sensusmethodology by which such analyses should be conducted, nor
anestablishedoptimal significance threshold for including loci,we sought
to be conservative, using only two of themany available approaches44,45
and restricting analyses to genes within genome-wide significant loci.
Neither approach identified gene-sets that were significantly enriched
for associations after correction for thenumberof pathways tested (Sup-
plementaryTable 5) althoughnominally significantly enrichmentswere
observed among several predefined candidate pathways (ExtendedData
Table1).A fuller exploratoryanalysisof thedatawill bepresentedelsewhere.
Overlap with rare mutations
CNVs associatedwith schizophrenia overlapwith those associatedwith
autismspectrumdisorder (ASD)and intellectual disability9, as do genes
with deleterious de novomutations34. Here we find significant overlap
betweengenes in the schizophreniaGWASassociated intervals and those
with de novo non-synonymousmutations in schizophrenia (P5 0.0061)
(Extended Data Table 2), suggesting that mechanistic studies of rare
genetic variation in schizophrenia will be informative for schizophrenia
morewidely.We also find evidence for overlap between genes in schizo-
phreniaGWAS regions and thosewith denovonon-synonymousmuta-
tions in intellectualdisability (P50.00024)andASD(P50.035),providing
further support for the hypothesis that these disorders have partly over-
lapping pathophysiologies9,34.
Polygenic risk score profiling
Previous studies have shown that risk profile scores (RPS) constructed
from alleles showing modest association with schizophrenia in a dis-
covery GWAS can predict case-control status in independent samples,
albeitwith low sensitivity and specificity10,11,16. This findingwas robustly
confirmed in the present study. The estimate of NagelkerkeR2 (amea-
sure of variance in case-control status explained) depends on the spe-
cific target data set and threshold (PT) for selecting risk alleles for RPS
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Figure 2 | Enrichment in enhancers of credible SNPs. Cell and tissue type
specific enhancers were identified using ChIP-seq data sets (H3K27ac signal)
from 56 cell line and tissue samples (y axis). We defined cell and tissue type
enhancers as the top 10%of enhancers with the highest ratio of reads in that cell
or tissue type divided by the total number of reads. Enrichment of credible
causal associated SNPs from the schizophrenia GWAS was compared with
frequency matched sets of 1000 Genomes SNPs (Supplementary Methods).
The x axis is the –log10 P for enrichment. P values are uncorrected for the
number of tissues or cells tested. A –log10 P of roughly 3 can be considered
significant after Bonferroni correction. Descriptions of cell and tissue types at
the Roadmap Epigenome website (http://www.roadmapepigenomics.org).
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analysis (ExtendedData Fig. 5 and 6a).However, using the same target
sample as earlier studies and PT5 0.05, R
2 is now increased from 0.03
(ref. 10) to 0.184 (ExtendedData Fig. 5). Assuming a liability-threshold
model, a lifetime risk of 1%, independent SNP effects, and adjusting for
case-control ascertainment, RPSnowexplains about 7%of variation on
the liability scale46 to schizophrenia across the samples (ExtendedData
Fig. 6b), about half of which (3.4%) is explained by genome-wide signi-
ficant loci.
We also evaluated the capacity of RPS to predict case-control status
using a standard epidemiological approach to a continuous risk factor.
We illustrate this in three samples, each with different ascertainment
schemes (Fig. 3). TheDanish sample is population-based (that is, inpa-
tient and outpatient facilities), the Swedish sample is based on all cases
hospitalized for schizophrenia in Sweden, and the Molecular Genetics
of Schizophrenia (MGS) sample was ascertained specially for genetic
studies from clinical sources in theUS andAustralia.We grouped indi-
viduals intoRPSdeciles and estimated the odds ratios for affected status
for each decile with reference to the lowest risk decile. The odds ratios
increasedwith greater number of schizophrenia risk alleles in each sam-
ple, maximizing for the tenth decile in all samples: Denmark 7.8 (95%
confidence interval (CI): 4.4–13.9), Sweden 15.0 (95% CI: 12.1–18.7)
and MGS 20.3 (95% CI: 14.7–28.2). Given the need for measures that
index liability to schizophrenia47,48, the ability to stratify individuals by
RPS offers newopportunities for clinical and epidemiological research.
Nevertheless, we stress that the sensitivity and specificity of RPS do not
support its use as a predictive test. For example, in the Danish epide-
miological sample, the area under the receiver operating curve is only
0.62 (Extended Data Fig. 6c, Supplementary Table 6).
Finally, seeking evidence for non-additive effects on risk, we tested
for statistical interaction between all pairs of 125 autosomal SNPs that
reached genome-wide significance. P values for the interaction terms
weredistributed according to thenull, andno interactionwas significant
after correction formultiple comparisons. Thus,we findno evidence for
epistatic or non-additive effects between the significant loci (Extended
Data Fig. 7). It is possible that such effects could be present between
other loci, or occur in the form of higher-order interactions.
Discussion
In the largest (to our knowledge)molecular genetic study of schizophre-
nia, or indeedof anyneuropsychiatric disorder, ever conducted,wedem-
onstrate the power of GWAS to identify large numbers of risk loci. We
show that the use of alternative ascertainment and diagnostic schemes
designed to rapidly increase sample size does not inevitably introduce a
crippling degree of heterogeneity. That this is true for a phenotype like
schizophrenia, inwhich there are nobiomarkers or supportive diagnostic
tests, provides grounds to be optimistic that this approach can be suc-
cessfully applied to GWAS of other clinically defined disorders.
We further show that the associations are not randomly distributed
across genes of all classes and function; rather they convergeupongenes
that are expressed in certain tissues andcellular types.The findings include
molecules that are the current, or themost promising, targets for ther-
apeutics, and point to systems that align with the predominant aeti-
ological hypotheses of the disorder. This suggests that the many novel
findings we report also provide an aetiologically relevant foundation
formechanistic and treatment development studies.We also findover-
lap between genes affected by rare variants in schizophrenia and those
within GWAS loci, and broad convergence in the functions of some of
the clusters of genes implicated by both sets of genetic variants, parti-
cularly genes related to abnormal glutamatergic synaptic and calcium
channel function.Howvariation in thesegenes impact function to increase
risk for schizophrenia cannot be answered by genetics, but the overlap
strongly suggests that common and rare variant studies are complemen-
tary rather than antagonistic, and thatmechanistic studies driven by rare
genetic variation will be informative for schizophrenia.
Online ContentMethods, along with any additional Extended Data display items
andSourceData, are available in theonline versionof thepaper; referencesunique
to these sections appear only in the online paper.
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Extended Data Figure 1 | Homogeneity of effects across studies. Plot of the
first two principal components (PCs) from principal components analysis
(PCA) of the logistic regression b coefficients for autosomal genome-wide
significant associations. The input data were the b coefficients from 52 samples
for 112 independent SNP associations (excluding 3 chrX SNPs and 13 SNPs
with missing values in Asian samples). PCAs were weighted by the number of
cases. Each circle shows the location of a study on PC1 and PC2. Circle size and
colour are proportional to the number of cases in each sample (larger and
darker red circles correspond tomore cases).Most samples cluster. Outliers had
either small numbers of cases (‘small’) or were genotyped on older arrays.
Abbreviations: a500 (Affymetrix 500K); a5 (Affymetrix 5.0). Studies that did
not use conventional research interviews are in the central cluster (CLOZUK,
Sweden, and Denmark-Aarhus studies, see Supplementary Methods for
sample descriptions).
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Extended Data Figure 2 | Quantile-quantile plot. Quantile-quantile plot of
the discovery genome-wide association meta-analysis of 49 case control
samples (34,241 cases and 45,604 controls) and 3 family based association
studies (1,235 parent affected-offspring trios). Expected –log10 P values are
those expected under the null hypothesis. Observed are the GWAS association
results derived by logistic regression (2-tailed) as in Fig. 1. For clarity, we
avoided expansion of the y axis by setting the smallest association P values to
10212. The shaded area surrounded by a red line indicates the 95% confidence
interval under the null. lGC is the observed median x
2 test statistic divided
by the median expected x2 test statistic under the null hypothesis.
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Extended Data Figure 3 | Linkage disequilibrium score regression
consistent with polygenic inheritance. The relationship between marker x2
association statistics and linkage disequilibrium (LD) as measured by the
linkage disequilibrium score. Linkage disequilibrium score is the sum of the
r2 values between a variant and all other known variants within a 1 cMwindow,
and quantifies the amount of genetic variation tagged by that variant. Variants
were grouped into 50 equal-sized bins based on linkage disequilibrium score
rank. Linkage disequilibrium score bin and mean x2 denotes mean linkage
disequilibrium score and test statistic for markers each bin. a, b, We simulated
(Supplementary Methods) test statistics under two scenarios: a, no true
association, inflation due to population stratification; and b, polygenic
inheritance (l5 1.32), in which we assigned independent and identically
distributed per-normalized-genotype effects to a randomly selected subset of
variants. c, Results from the PGC schizophrenia GWAS (l5 1.48). The real
data are strikingly similar to the simulated data summarized in b but not a. The
intercept estimates the inflation in the mean x2 that results from confounding
biases, such as cryptic relatedness or population stratification. Thus, the
intercept of 1.066 for the schizophrenia GWAS suggests that ,90% of the
inflation in the mean x2 results from polygenic signal. The results of the
simulations are also consistentwith theoretical expectation (see Supplementary
Methods). l is the median x2 test statistic from the simulations (a, b) or the
observed data (c) divided by the median expected x2 test statistic under the
null hypothesis.
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Extended Data Figure 4 | Enrichment of associations in tissues and cells.
Genes whose transcriptional start is nearest to the most associated SNP at each
schizophrenia-associated locus were tested for enriched expression in purified
brain cell subsets obtained from mouse ribotagged lines41 using enrichment
analysis described in the SupplementaryMethods. The red dotted line indicates
P5 0.05.
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Extended Data Figure 5 | MGS risk profile score analysis. Polygenic risk
profile score (RPS) analyses using theMGS18 sample as target, and deriving risk
alleles from three published schizophrenia data sets (x axis): ISC (2,615
cases and 3,338 controls)10, PGC1 (excluding MGS, 9,320 cases and 10,228
controls)16, and the current meta-analysis (excluding MGS) with 32,838 cases
and 44,357 controls. Samples sizes differ slightly from the original publications
due to different analytical procedures. This shows the increasing RPS
prediction with increasing training data set size reflecting improved precision
of estimates of the SNP effect sizes. The proportion of variance explained
(y axis; Nagelkerke’s R2) was computed by comparison of a full model
(covariates 1 RPS) score to a reduced model (covariates only). Ten different
P value thresholds (PT) for selecting risk alleles are denoted by the colour of
each bar (legend above plot). For significance testing, see the bottom legend
which denotes the P value for the test that R2 is different from zero. All
numerical data and methods used to generate these plots are available in
Supplementary Table 6 and Supplementary Methods.
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Extended Data Figure 6 | Risk profile score analysis. We defined 40 target
subgroups of the primary GWAS data set and performed 40 leave-one-out
GWAS analyses (see Supplementary Methods and Supplementary Table 7)
from which we derived risk alleles for RPS analysis (x axis) for each target
subgroup. a, The proportion of variance explained (y axis; Nagelkerke’sR2) was
computed for each target by comparison of a full model (covariates 1 RPS)
score to a reduced model (covariates only). For clarity, 3 different P value
thresholds (PT) are presented denoted by the colour of each bar (legend above
plot) as for Extended Data Fig. 5, but for clarity we restrict to fewer P value
thresholds (PT of 53 10
28, 13 1024 and 0.05) and removed the significance
values. b, The proportion of variance on the liability scale from risk scores
calculated at the PT 0.05 with 95%CI bar assuming baseline population disease
risk of 1%. c, Area under the receiver operating curve (AUC). All numerical
data and methods used to generate these plots are available in Supplementary
Table 7 and Supplementary Methods.
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Extended Data Figure 7 | Pairwise epistasis analysis of significant SNPs.
Quantile-quantile plot for all pair-wise (n5 7,750) combinations of the 125
independent autosomal genome-wide significant SNPs tested for non-additive
effects on risk using case-control data sets of European ancestry (32,405 cases
and 42,221 controls). We included as covariates the principal components
from the main analysis as well as a study indicator. The interaction model is
described by:
Y~b0za^1X1za^2X2za^3  X1X2za^4X4za^5X5
X1 andX2 are genotypes at the two loci,X1X2 is the interaction between the two
genotypes modelled in a multiplicative fashion, X4 is the vector of principal
components, X5 is the vector of study indicator variables. Each a^ is the
regression coefficient in the generalized linear model using logistic regression.
The overall distribution of P values did not deviate from the null and the
smallest P value (4.283 1024) did not surpass the Bonferroni correction
threshold (P5 0.05/77505 6.453 1026). The line x5 y indicates the expected
null distributionwith the grey area boundedby red lines indicating the expected
95% confidence interval for the null.
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Extended Data Table 1 | ALIGATOR and INRICH
Gene sets that have been reported to be enriched for schizophrenia associations and or rare mutations were tested for enrichment for genome-wide significant associations using ALIGATOR44 and INRICH45.
Specifically, we tested the glutamatergic postsynaptic proteins comprising activity-regulated cytoskeleton-associated protein (ARC) and N-methyl-D-aspartate receptor (NMDAR) complexes33–35, other curated
synaptic gene-sets14,49, targets of fragile X mental retardation protein (FMRP)33–35, calcium channels11,33, and TargetScan predicted MIR137 sets11,16. The MIR137 TargetScan sets contain computationally
predicted conservedmiRNA target sites in 39UTRs of human genes50. The current version is v6, but the version used in the prior PGC SCZ report16 was based on v5 (filtered for a probability of conserved targeting
.0.9).We report the results of both analyses for consistencywithpreviouswork. The associationat the extendedMHCcomplexwasnot includedgiven the extensive linkagedisequilibriumat this region spans large
numbers of genes. NA means that the pathway in question contained fewer than 2 significant genes (for ALIGATOR) or regions (INRICH).
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Extended Data Table 2 | de novo overlap
Test of overlap between genes mapping to schizophrenia-associated loci in the present study and genes affected by non-synonymous (NS) de novomutations. Enrichment was calculated using the dnenrich
permutation framework as described34. Genes within the GWS loci (Supplementary Table 3) were weighted by 1/N, whereN is the number of coding genes within each associated locus. The observed test statistic
(stat) is the sum of weights of genes impacted by de novomutations. The expected test statistics are calculated by averaging over 50,000 permuted de novomutation sets. Genes within schizophrenia-associated
loci affectedbyde novomutations are listed (multiple hits listed inparentheses). Cohorts: SCZ, schizophrenia; ID, intellectual disability; ASD, autismspectrumdisorder. Allmutations analysedannotated according
to a unified system (see Supplementary Tables 1 and 2 of ref. 34). Genes with loss-of-function de novomutations are underlined and in italics.
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